Results 111 to 120 of about 5,729,125 (133)

Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. [PDF]

Cancer Res Commun, 2023
Pillsbury CE, Dougan J, Rabe JL, Fonseca JA, Zhou C, Evans AN, Evans AN, Abukharma H, Ichoku O, Gonzalez-Flamenco G, Park SI, Aljudi A, DeRyckere D, Castellino SM, Rafiq S, Langermann S, Liu LN, Henry CJ, Porter CC.   +18 more
europepmc   +1 more source

Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma. [PDF]

Virchows Arch, 2023
Mutka M, Joensuu K, Heiskala M, Eray M, Heikkilä P.   +4 more
europepmc   +1 more source

Mechanisms of tumor immune escape mediated by Siglec-15 and advances and prospects in targeted therapy

Zhongguo aizheng zazhi
Immune checkpoint blockade targeting the programmed cell death protein-1 (PD-1) and its ligand PD-L1 has revolutionized cancer immunotherapy; however, a substantial proportion of patients exhibit primary or acquired resistance, underscoring the existence
WANG Shihui, ZHENG Tianqing
doaj  

Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions. [PDF]

J Immunother, 2023
Ding H, Yao B, Ci L, Feng J, Ouyang P, Chen G, Hui X, Zhou D.   +7 more
europepmc   +1 more source

Siglec-15 Expression in Gastric Carcinoma and Its Association With Clinicopathological Variables. [PDF]

World J Oncol
Al Badr S, Battah A, Alsughayer A, Alsmarat F, Halahleh K, Sughayer M.   +5 more
europepmc   +1 more source

Association between DPAGT1 and Siglec-15 expression and the malignant phenotype of hepatocellular carcinoma. [PDF]

Am J Cancer Res
Luo M, Wang X, Wang H, Liu Y, Huang C, Wei H.   +5 more
europepmc   +1 more source

Siglec‑15 dysregulation and its therapeutic implications in new‑onset type 1 diabetes. [PDF]

Int J Mol Med
Guo H, Tao Y, Li S, Gu Y, Huang Y, Fang C, Hu J.   +6 more
europepmc   +1 more source

Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. [PDF]

Lab Invest, 2022
Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL.   +11 more
europepmc   +1 more source

Siglec-15 Enhances Cisplatin Resistance in Cervical Cancer Cells by Promoting Mitochondrial Retrograde Signaling Through Activation of the MAPK Pathway

Chemoresistance constitutes a major cause of poor prognosis in advanced cervical cancer. Our previous studies have confirmed that Siglec-15 affects the progression of cervical cancer, whereas its role in regulating cervical cancer ...
Li Hao, Zenghui Li, Junwei Zhao, Jing Wang   +3 more
core   +1 more source

Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence. [PDF]

Int J Med Sci, 2022
Cui L, Tian X, Yan L, Guan X, Dong B, Zhao M, Lv A, Liu D, Wu J, Hao C.   +9 more
europepmc   +1 more source